Could a common ED drug shield prostate cancer patients from chemo nerve pain?
NCT ID NCT07333976
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether tadalafil, a drug often used for erectile dysfunction, can prevent nerve damage caused by docetaxel chemotherapy in men with metastatic prostate cancer. 90 participants were randomly assigned to receive either tadalafil plus standard care or standard care alone. The goal was to see if tadalafil reduces the number of patients who develop painful or limiting nerve symptoms during treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tri-Service General Hospital
Taipei, Neihu, 114, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Glow-in-the-dark dye may help surgeons spot hidden prostate cancer cells
- Acupuncture vs. sham needles: a test for chemo nerve damage
- Video analysis could personalize rehab for chemo nerve damage
- Brain training and nerve stretching could ease chemo nerve damage
- Acupuncture and exercise join forces against chemotherapy nerve pain
- New drug candidate AH-008 takes first step toward easing chemotherapy nerve pain